Literature DB >> 191523

Biologic and chemical characterization of HLA antigens in human serum.

J P Allison, M A Pellegrino, S Ferrone, G N Callahan, R A Reisfeld.   

Abstract

HLA antigens of both the A and B loci were shown to be associated with the high density lipoprotein fraction of serum prepared by ultracentrifugal flotation. HLA-A9 antigens were purified 100-fold with essentially complete recovery by a simple procedure of high density lipoprotein preparation involving precipitation with polyanions and ultracentrifugal flotation. The purified lipid-associated antigen was immunogenic since it elicited the formation of cytotoxic xenoantibodies in rabbits. Serum HLA-A9 antigens were found by immunoprecipitation and gel electrophoresis to consist of a 45,000 m.w. heavy chain associated with beta2-microglobulin. The size of the HLA-lipid complex (less than 190,000 m.w.) and of the HLA-deoxycholate complex (less than 102,000 m.w.) suggests that HLA antigens are shed into plasma as a complex of a single HLA molecule and a single beta2-microglobulin chain, associated with boundary lipid.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 191523

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Soluble beta2-mu-associated and beta2-mu-free HLA class I heavy chain serum levels in interferon-alpha nonresponder chronic hepatitis C patients. Markers of immune activation, and response to antiviral retreatment.

Authors:  F Puppo; F Torre; P Contini; M Ghio; S Brenci; R Brizzolara; N Sinelli; N Campo; F Indiveri; A Picciotto
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

2.  Measurement of HLA class I expression in ankylosing spondylitis.

Authors:  P Creamer; J Edmonds; J Sullivan; S Matthews
Journal:  Ann Rheum Dis       Date:  1992-10       Impact factor: 19.103

3.  Soluble class I histocompatibility antigens (s-HLA) and beta 2-microglobulin at delivery.

Authors:  A Ferreira; M C García Rodríguez; F Omeñaca; A Jiménez; L M Villar; P Gonzalez-Porqué; G Fontán
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

4.  Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy.

Authors:  Giuseppe Murdaca; Paola Contini; Paola Cagnati; Simona Marenco; Giulia Pieri; Francesca Lantieri; Antonino Picciotto; Francesco Puppo
Journal:  Clin Exp Med       Date:  2015-11-14       Impact factor: 3.984

5.  Quantification of soluble HLA class I gene products by an enzyme linked immunosorbent assay.

Authors:  I Doxiadis; U Westhoff; H Grosse-Wilde
Journal:  Blut       Date:  1989-11

6.  Induction of cell-mediated cytotoxicity by lipoprotein containing histocompatibility antigens.

Authors:  G Dennert
Journal:  Immunology       Date:  1979-12       Impact factor: 7.397

7.  A factor shed by lymphoblastoid cell lines of HLA-B27 positive patients with ankylosing spondylitis, specifically modifies the cells of HLA-B27 positive normal individuals.

Authors:  P Orban; J S Sullivan; A F Geczy; L I Upfold; N Coulits; H V Bashir
Journal:  Clin Exp Immunol       Date:  1983-07       Impact factor: 4.330

8.  Production of a tumor-specific xenoantiserum from partially purified immunoprotective tumor antigen.

Authors:  T Tanaka; H Yamagishi; N R Pellis; B D Kahan
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

9.  Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: an early predictor marker of response?

Authors:  F Puppo; A Picciotto; S Brenci; G Varagona; M Scudeletti; M Ghio; V Balestra; G Celle; F Indiveri
Journal:  J Clin Immunol       Date:  1995-07       Impact factor: 8.317

10.  A potential role for shed soluble major histocompatibility class I molecules as modulators of neurite outgrowth.

Authors:  Lorraine R Washburn; Dan Zekzer; Shoshana Eitan; Yuxin Lu; Hoa Dang; Blake Middleton; Christopher J Evans; Jide Tian; Daniel L Kaufman
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.